Gene-editing technique to treat lung cancer is due to be tested in people in August
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique.
A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. The clinical trial received ethical approval from the hospital’s review board on July 6.
“It’s an exciting step forward,” says Carl June, a clinical researcher in immunotherapy at the University of Pennsylvania in Philadelphia.
There have been a number of human clinical trials using an alternative gene-editing technique, including one led by June, that have helped patients combat HIV. June is also a scientific adviser on a planned US trial that would also use CRISPR–Cas9-modified cells for the treatment of cancer.
Last month, an advisory panel of the US National Institutes of Health (NIH) approved that project. But the trial also requires a green light from the US Food and Drug Administration (FDA) and a university review board. The US researchers have said they could start their clinical trial by the end of this year.
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed. “Treatment options are very limited,” says Lu. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Synthego Presents at the 7th Annual CAR-TCR Summit: Company highlights innovative solutions to accelerate CRISPR-based medicines from bench to clinicon September 20, 2022 at 6:21 am
Synthego, the genome engineering company, today announced that Rebecca Nugent, Ph.D., vice president of platform research at Synthego, will be presenting during the 7th Annual CAR-TCR Summit taking ...
- New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errorson September 20, 2022 at 1:35 am
A new CRISPR startup is planning to develop gene-editing treatments that can insert a genetic sequence of any length, at any location in the DNA strand, according to industry insiders and documents.
- CRISPR/CAS 9 Technology Market Size Worth USD 6,221 Million In 2028-Emergen Researchon September 20, 2022 at 1:34 am
Emergen Research Logo Steady CRISPR/CAS 9 market revenue growth is due to its ability to correct genetic defects, yield better crop varie ...
- Research Analysts Offer Predictions for CRISPR Therapeutics AG’s Q3 2022 Earnings (NASDAQ:CRSP)on September 18, 2022 at 10:12 pm
Investment analysts at Zacks Research issued their Q3 2022 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued on Wednesday, September 14th. Zacks Research analyst ...
- CRISPR infusion helps stop swelling caused by genetic disease - studyon September 18, 2022 at 10:07 am
The new treatment has kept patients attack free and allowed them to stop taking medication in interim results.
- Crispr Gene-Editing Drugs Show Promise in Preliminary Studyon September 16, 2022 at 1:03 pm
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
- Intellia says CRISPR treatment safely corrects DNA of six patients with rare diseaseon September 16, 2022 at 12:32 pm
Intellia Therapeutics said Friday the first six patients to receive its CRISPR-based treatment for a genetic swelling disorder have safely had small, corrective changes made to dysfunctional DNA ...
- Intellia falls as analysts react to CRISPR readoutson September 16, 2022 at 9:16 am
Gene-editing company Intellia Therapeutics, Inc. (NTLA) reversed pre-market gains on Friday morning as Wall Street weighed in on the company’s early data readouts ...
- Intellia posts promising early results from two CRISPR gene editing studieson September 16, 2022 at 4:15 am
Just weeks after patients received infusions of the experimental therapies, they experienced a dramatic reduction in blood markers linked to their diseases.
- Crispr Therapeutics becomes the latest biotech to open in the Seaporton September 15, 2022 at 7:23 am
The gene editing company has moved from Kendall Square to a headquarters in what is becoming a new life sciences hub.
via Bing News